↓ Skip to main content

Gemcitabine and CHK1 Inhibition Potentiate EGFR-Directed Radioimmunotherapy against Pancreatic Ductal Adenocarcinoma

Overview of attention for article published in Clinical Cancer Research, June 2014
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (71st percentile)
  • Above-average Attention Score compared to outputs of the same age and source (54th percentile)

Mentioned by

twitter
2 X users
patent
1 patent

Citations

dimensions_citation
32 Dimensions

Readers on

mendeley
35 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Gemcitabine and CHK1 Inhibition Potentiate EGFR-Directed Radioimmunotherapy against Pancreatic Ductal Adenocarcinoma
Published in
Clinical Cancer Research, June 2014
DOI 10.1158/1078-0432.ccr-14-0048
Pubmed ID
Authors

Fares Al-Ejeh, Marina Pajic, Wei Shi, Murugan Kalimutho, Mariska Miranda, Adnan M. Nagrial, Angela Chou, Andrew V. Biankin, Sean M. Grimmond, Michael P. Brown, Kum Kum Khanna

X Demographics

X Demographics

The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 35 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Japan 1 3%
United States 1 3%
France 1 3%
Unknown 32 91%

Demographic breakdown

Readers by professional status Count As %
Researcher 8 23%
Student > Bachelor 7 20%
Student > Ph. D. Student 6 17%
Other 3 9%
Student > Master 3 9%
Other 2 6%
Unknown 6 17%
Readers by discipline Count As %
Medicine and Dentistry 11 31%
Agricultural and Biological Sciences 8 23%
Biochemistry, Genetics and Molecular Biology 6 17%
Nursing and Health Professions 1 3%
Pharmacology, Toxicology and Pharmaceutical Science 1 3%
Other 1 3%
Unknown 7 20%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 January 2019.
All research outputs
#6,778,124
of 22,756,196 outputs
Outputs from Clinical Cancer Research
#6,169
of 12,571 outputs
Outputs of similar age
#64,888
of 228,694 outputs
Outputs of similar age from Clinical Cancer Research
#66
of 163 outputs
Altmetric has tracked 22,756,196 research outputs across all sources so far. This one has received more attention than most of these and is in the 69th percentile.
So far Altmetric has tracked 12,571 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.7. This one has gotten more attention than average, scoring higher than 50% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 228,694 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 71% of its contemporaries.
We're also able to compare this research output to 163 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 54% of its contemporaries.